Agents acting on the renin–angiotensin system were under-prescribed in our sample, whereas angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors are effective to reduce all-cause mortality and cardiovascular mortality in people at high risk of heart failure [45]. The gene discussed is REN; the disease is heart failure.